Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 12/20 | 0.58 |
| ▸ | EDNRB | P24530 | 6/20 | 0.51 |
| ▸ | CCR9 | P51686 | 3/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | DHPS | P49366 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7573691 | 0.94 | EDNRA (0.58) | EDNRAEDNRBCCR9ABCC3ABCC4 | |
| SCHEMBL7566496 | 0.93 | EDNRB (0.55) | EDNRAEDNRBFABP4KDM4EALDH1A1 | |
| SCHEMBL7567944 | 0.93 | EDNRA (0.58) | EDNRAEDNRBFABP4KDM4EALDH1A1 | |
| SCHEMBL7567454 | 0.90 | EDNRB (0.65) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7565811 | 0.88 | EDNRB (0.65) | EDNRAEDNRB | |
| SCHEMBL7567778 | 0.87 | EDNRA (0.64) | EDNRAEDNRBCCR9ALDH1A1LMNA | |
| SCHEMBL7567784 | 0.87 | EDNRA (0.59) | EDNRAEDNRBCCR9ABCC3ABCC4 | |
| SCHEMBL7573361 | 0.87 | EDNRB (0.53) | EDNRAEDNRBALDH1A1LMNA | |
| SCHEMBL7566622 | 0.86 | EDNRA (0.58) | EDNRAEDNRBCCR9ALDH1A1LMNA | |
| SCHEMBL7565809 | 0.86 | EDNRA (0.77) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0799206-B1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | claimed |
| US-5962682-A | Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists | HOFFMANN-LA ROCHE INC. (US) | 1999-10-05 | — | — | US | claimed |
| JP-2930731-B2 | — | — | 1999-08-03 | — | — | JP | claimed |
| EP-0799206-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | claimed |
| WO-1996019455-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | claimed |
| EP-0799206-B1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| US-6133442-A | FOR THE TREATMENT OF DISORDERS WHICH ARE ASSOCIATED WITH ENDOTHELIN ACTIVITIES, ESPECIALLY CIRCULATORY DISORDERS SUCH AS HYPERTENSION, ISCHAEMIA, VASOSPASMS AND ANGINA PECTORIS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-5962682-A | Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists | HOFFMANN-LA ROCHE INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0799206-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019455-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | disclosed |